EGFR-tyrosine kinase inhibitors (TKIs) have exhibited significant effects against NSCLC with EGFR mutations3, 4, 5, however, patients who initially respond to EGFR-TKIs eventually acquire resistance, which is a critical problem in the treatment of patients with advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.